Idarucizumab

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Idarucizumab
   1. Pharmacist Assessment Report
   2. Idarucizumab: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Idarucizumab: Known uses and market status in Canada

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Idarucizumab, so there is currently no new predicted indication. The drug’s own recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	2
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 1 of 1)
Number of DINs	1 (marketed: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
hemorrhage	licence in another country
in life-threatening or uncontrolled bleeding	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Canada Market Information

Licence	Product	Dosage form	Status
02454343	PRAXBIND		Valid

Safety Considerations

Please refer to the package insert for safety information. No drug interactions were found in the data compiled for this report, and no contraindication data from the knowledge graph were available.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---